Logotype for Evotec SE

Evotec (EVT) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Evotec SE

Q3 2026 earnings summary

5 Nov, 2026

Executive summary

  • Q3 revenue was broadly stable YoY and adjusted EBITDA improved to near break-even; 9M revenue declined, while D&PD base-business net sales rose 24%.

  • FY 2026 guidance was reaffirmed, with revenue and adjusted EBITDA expected toward the upper ends of their ranges.

  • The 2030 framework targets ~€1bn revenue and an adjusted EBITDA margin above 20%.

Financial highlights

  • Q3 group revenue was €164.9m, up 0.6% YoY; at constant exchange rates it was €164.2m versus €163.9m.

  • 9M group revenue was €465.0m, down 13.1% reported and 10.8% at constant exchange rates; base revenue fell 12.4% to €441.1m.

  • Q3 adjusted group EBITDA loss narrowed to €1.6m from €15.0m; the 9M loss widened to €44.3m from €16.9m, or €39.1m at constant exchange rates.

  • 9M gross profit was €16.6m and gross margin 3.6%, versus €57.1m and 10.7% a year earlier.

  • 9M operating loss was €254.8m and net loss €195.3m; reorganization costs were €91.9m and included a €42.3m Hamburg laboratory impairment.

Outlook and guidance

  • FY 2026 guidance remains €570m–€610m revenue reported (€595m–€635m at constant FX) and an adjusted EBITDA loss of €70m–€105m (€60m–€90m at constant FX); both are expected toward the upper ends.

  • Horizon targets ~€75m annual run-rate savings by end-2027; more than 20% had been delivered by September, with 20%–30% planned for 2026.

  • The 2028 mid-range plan targets a 20% adjusted EBITDA margin; 2030 targets ~€1bn revenue and an adjusted EBITDA margin above 20%.

  • 2030 revenue mix targets are 40% D&PD base business, 20% strategic partnerships and 40% JEB.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Evotec